India: Can Compulsory License (CL) Be A Legal Tool For Pharmaceutical Industry? ‘An Overview Of The CL Under The Indian Pharma Industry

As the grant of Compulsory license (CL) to Natco to make and sell generic version of Bayer AG's patented cancer treatment Nexavar might be an old story under the India's IP regime but it is first CL to be issued in the history of the Indian Patents system. It's the first time that an Indian company has been granted a compulsory licence to market a generic version of a patented drug. After this order, Indian IPR has garnered a lot of attention globally. Recently, The U.S. Chamber of Commerce called on the Indian government to ratchet up pressure on India over intellectual property rights, in a move that could help prevent Indian companies from producing cheap generic versions of medicines still under patent protection1. The U.S government clearly want to allow US pharma companies to sell their patented drugs at the high price in the Indian market. These issues are the outcome of the grant of first CL issued in India.

Compulsory License- The grant of compulsory licensing is a remedy to control abuse of exclusivity which is protected by IP rights. Today, lot of countries have issued compulsory licenses in the interest of mankind. Accordingly, it has been viewed that after the compliance of TRIPS, countries such as Brazil, Thailand, Malaysia, South Africa, Kenya, Ecuador etc. have issued compulsory licenses over the patent rights of AIDS drugs and in 2012 India has also joined the bandwagon of compulsory licensing2. Before moving ahead, it is essential to summon up the definition of compulsory license. Compulsory licenses are involuntary contracts between willing buyer and unwilling seller imposed or enforced by the authorized body. It is a legal instrument designed to force intellectual property owners to license out their statutorily granted right to interested third parties capable of manufacturing the patented product at cheaper prices. In the year 2012, a landmark decision of India's intellectual property office came which granted the first CL to Natco to sell Bayer's patented chemotherapy drug Nexavar (sorafenib tosylate). Compulsory licensing of IPR in India brings another opportunity for Indian Pharmaceutical industry which is 3rd largest industry in the world after US and Japan. In India there are many Indian & MNC Pharma industries where most of them produce generic drugs. Productions of such drugs are relatively lesser in cost as compared to patented drugs and can be easily approached by needy patients. In such a way, most of the Indian Pharma companies established their presence in India and in the market whereas MNC companies who have also established their presence in India and from past many years, these MNC are contributing their enormous presence in the research and development, clinical testing/trials, and further in grant of patents. These companies invest huge amount of money in getting their drugs patented and in protecting their drug against legal actions. In considering the example of the Bayer vs. Natco where IPO grant Natco to sell Bayer's patented drug at an affordable price. Such CL is in favour of betterment of the mankind and to the better health scenario in the country. But considering from the perceptive of those MNC companies, such compulsory licensing may deter R&D, monetary investment, foreign direct investment in Pharma industrial sectors. Such apprehensions of compulsory licensing of IPRs may cause companies to not to venture in to Indian jurisdiction as their right of patent or any other IPR may be licensed to others bringing down the profitability. It can be seen in the Bayer vs. Natco where IPO has sanctioned only 6% of the profits from sale of sofranib by Natco. This indicates that though the profits earned by the IP are much proportional to compulsory license but still it doesn't vanish completely. The royalty earned, which might not be sufficient for Bayer but for the sake of mankind it must be a healthy step.

Grant of compulsory license in the country increases the competition among the Pharma companies but this creates the sense of mistrust between those companies who spends and invests lot of money and their resources to invent a novel drug. In one of the famous saying which give rise to a conclusion suitably fits for this compulsory licensing. According to it, "when the situation has become highly problematic, it is appropriate to use corrective actions that are considered more extreme than usual". Therefore, it is concluded that drastic measures of compulsory license must be used only in drastic times and if this is not been followed than it might be a tough time for Pharmaceutical industry to flourish in India and for healthy India.

Further considering the consequences of compulsory licensing:


The decision of first compulsory licensing might vanish the India's strong IP regime globally. Innovator companies who invest large amount of money in innovation will not feel secure enough to invest in the country where their researched products (incurring millions of dollars) are exploited by lowering the cost3.


Firstly, it can be observed from the CL that it is meant for providing necessary medicines at an affordable cost. But such step of government may demolish the practise of domestic companies to invest in R&D, because a company would not risk the huge expenditures involved in research when with a single decision of the government can allow another company to copy the product legally at a negligible cost. Secondly, this step might harness the relationship between domestic Pharma companies and their foreign counterparts4.

Case: In one of the Compulsory License application made by M/s. BDR Pharmaceuticals against the Bristol Myer Squibb Company.

On 30th October, 2013, IPO rejected the compulsory license application filed by the BDR pharmaceuticals against the Bristol's patented drug Sprycel (dasatinib) which is used by patients suffering from chronic myeloid leukaemia herein-after referred to as "CML5". The drug was sold at a price of Rs. 2761 by the patentee in the Indian market which won't be accessible to many patients because of its high price.

In this case IPO rejected the application because applicant failed to comply with the prima facie case for the grant of compulsory licence, under Section 87 of the Indian Patents Act. Further, IPO states that the applicant did not make efforts to obtain a licence from the patentee on reasonable terms and conditions. This is the second compulsory license application filed in the country. In referring this case, the IPO denied the allegations of MNCs Pharma companies that India issues compulsory licences blindly.






5. made-to-usitcs-nvestigation-into-theindian- patent-regime.html

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Khurana and Khurana
InvnTree Intellectual Property Services Pvt. Ltd.
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Khurana and Khurana
InvnTree Intellectual Property Services Pvt. Ltd.
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions